靶向CD317的嵌合抗原受体T细胞作为胶质母细胞瘤新型免疫治疗策略
研究鉴定跨膜蛋白CD317为胶质母细胞瘤CAR-T治疗新靶点,用慢病毒转导健康供者T细胞制备CD317-CAR-T,体外显示对多种胶质瘤细胞系及原代患者细胞的抗肿瘤活性,CRISPR/Cas9敲除CD317可保护胶质瘤细胞免受裂解,RNA干扰沉默T细胞CD317表达减少自相残杀并改善效应功能,原位胶质瘤小鼠模型中CD317-CAR-T表现出抗原特异性抗肿瘤活性,延长生存并治愈部分治疗动物。
要点
- CD317被鉴定为胶质母细胞瘤CAR-T治疗的新靶抗原。
- CD317-CAR-T体外对多种胶质瘤细胞系及原代患者细胞有强抗肿瘤活性。
- 原位胶质瘤小鼠模型中CD317-CAR-T延长生存并治愈部分动物。
核心结论
- CD317-CAR-T细胞疗法在胶质母细胞瘤中显示出有前景的作用,值得进一步评估以将该免疫治疗策略转化至临床神经肿瘤学。
研究设计与样本
- 用慢病毒转导健康供者人T细胞生成靶向CD317的CAR-T细胞。
- 体外用细胞裂解实验评估CD317-CAR-T对多种胶质瘤细胞的抗胶质瘤活性。
- 随后在临床相关小鼠胶质瘤模型中确定CD317-CAR-T控制肿瘤生长的体内疗效。
主要发现
- CD317-CAR-T对多种CD317表达水平不同的胶质瘤细胞系及原代患者来源细胞在体外表现出强抗肿瘤活性。
- CRISPR/Cas9介导的CD317敲除保护胶质瘤细胞免受CAR-T细胞裂解,证明该方法的靶点特异性。
- RNA干扰沉默T细胞CD317表达减少工程化T细胞的自相残杀并进一步改善其效应功能。
- 原位胶质瘤小鼠模型中CD317-CAR-T表现出抗原特异性抗肿瘤活性,使生存期延长并治愈部分CAR-T治疗动物。
临床怎么用
- 作者认为CD317-CAR-T细胞疗法在胶质母细胞瘤中具有前景,值得进一步评估以将该免疫治疗策略转化至临床神经肿瘤学。
局限性
- 原文结论指出该策略值得进一步评估以转化至临床神经肿瘤学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has proven to be successful against hematological malignancies. However, exploiting CAR T cells to treat solid tumors is more challenging for various reasons including the lack of suitable target antigens. Here, we identify the transmembrane protein CD317 as a novel target antigen for CAR T cell therapy against glioblastoma, one of the most aggressive solid tumors. METHODS: CD317-targeting CAR T cells were generated by lentivirally transducing human T cells from healthy donors. The anti-glioma activity of CD317-CAR T cells toward various glioma cells was assessed in vitro in cell lysis assays. Subsequently, we determined the efficacy of CD317-CAR T cells to control tumor growth in vivo in clinically relevant mouse glioma models. RESULTS: We generated CD317-specific CAR T cells and demonstrate strong anti-tumor activity against several glioma cell lines as well as primary patient-derived cells with varying CD317 expression levels in vitro. A CRISPR/Cas9-mediated knockout of CD317 protected glioma cells from CAR T cell lysis, demonstrating the target specificity of the approach. Silencing of CD317 expression in T cells by RNA interference reduced fratricide of engineered T cells and further improved their effector function. Using orthotopic glioma mouse models, we demonstrate the antigen-specific anti-tumor activity of CD317-CAR T cells, which resulted in prolonged survival and cure of a fraction of CAR T cell-treated animals. CONCLUSIONS: These data reveal a promising role of CD317-CAR T cell therapy against glioblastoma, which warrants further evaluation to translate this immunotherapeutic strategy into clinical neuro-oncology.
引用
- Hänsch L, Peipp M, Mastall M, et al. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma. Neuro Oncol. 2023. PMID: 37335916. doi:10.1093/neuonc/noad108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。